CRISPR Therapeutics AG (NASDAQ:CRSP) saw a downside of -1.24% to close Friday at $45.49 after subtracting -$0.57 on the day. The 5-day average trading volume is 895,900 shares of the company’s common stock. It has gained $50.58 in the past week and touched a new high 1 time within the past 5 days. An average of 789,080 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 960,120.
CRSP’s 1-month performance is -9.92% or -$3.48 on its low of $45.18 reached on 09/21/23. The company’s shares have touched a 52-week low of $38.94 and high of $72.00, with the stock’s rally to the 52-week high happening on 05/23/23. YTD, CRSP has achieved 11.91% or $4.84 and has reached a new high 14 times. However, the current price is down -36.82% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CRSP stock investors last saw insider trading activity on May 30.Kulkarni Samarth (Chief Executive Officer) most recently sold 25,000 shares at $64.88 per share on May 30. This transaction cost the insider $1,621,894. Chief Executive Officer, Kulkarni Samarth, sold 25,000 shares at a price of $50.67 on Apr 25. Then, on Mar 29, Chief Executive Officer Kulkarni Samarth sold 25,000 shares at a price of $44.46 per share. This transaction amounted to $1,111,504.
Valuation Metrics
CRSP stock has a beta of 1.61. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 21.24 while the price-to-book (PB) in the most recent quarter is 1.99.
CRISPR Therapeutics AG’s quick ratio for the period ended June 29 was 14.00, with the current ratio over the same period at 14.00. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.13, while the total debt to equity was 0.14. In terms of profitability, the gross margin trailing 12 months is 32.67%. The trailing 12-month EBITDA margin is -54172.70% while for the period ending June 29, CRISPR Therapeutics AG’s operating margin was -278.45%. The firm’s gross profit as reported stood at $674.36 million against revenue of $1.2 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -139.04% to -$77.74 million, while revenue of -$53.07 million was 31.73% off the previous quarter. Analysts expected CRSP to announce -$2.12 per share in earnings in its latest quarter, but it posted -$0.98, representing a 53.80% surprise. EBITDA for the quarter stood at more than -$90.26 million. CRSP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 380.99 million, with total debt at $245.18 million. Shareholders hold equity totaling $79.41 million.
Let’s look briefly at CRISPR Therapeutics AG (CRSP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 28.72% to suggest the stock is trending oversold, with historical volatility in this time period at 35.80%.
The stock’s 5-day moving average is $46.63, reflecting a -10.06% or -$5.09 change from its current price. CRSP is currently trading -8.38% above its 20-day SMA, -7.31% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -22.90% and SMA200 by-12.70%.
Stochastic %K and %D was 6.19% and 4.98% and the average true range (ATR) pointed at 1.74. The RSI (14) points at 33.94%, while the 14-day stochastic is at 4.60% with the period’s ATR at 1.80. The stock’s 9-day MACD Oscillator is pointing at -2.27 and -3.00 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for CRISPR Therapeutics AG (NASDAQ: CRSP), Citigroup upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for CRSP stock have a consensus rating for the stock as Overweight. Currently, 2 brokerage advisors rate CRSP as a “sell,”, while 10 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 16 have offered a “buy” rating.
What is CRSP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $43.00 and a high of $220.00, with their median price target at $74.50. Looking at these predictions, the average price target given by analysts is for CRISPR Therapeutics AG (CRSP) stock is $87.17.
